Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.322 SEK | -0.31% | +8.05% | -96.78% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.78% | 47.48M | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Martin Amark, CEO for Xbrane Biopharma AB, becomes Head of IR